Cibus (CBUS) Non Operating Income (2016 - 2026)
Cibus (CBUS) posted Non Operating Income of $55000.0 for Q4 2025, down 65.19% sequentially from $158000.0 in Q3 2025, and down 49.54% YoY from $109000.0 in Q4 2024.
Cibus (CBUS) Non Operating Income (2016 - 2026) Analysis & Trends
Cibus has reported Non Operating Income for 10 years, with the latest figure at $55000.0 in Q4 2025.
- Quarterly Non Operating Income fell 49.54% year-over-year to $55000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $438000.0 (down 30.59% YoY) and the FY2025 annual result came in at $438000.0, down 30.59% from the prior year.
- Non Operating Income slipped to $55000.0 in Q4 2025 per CBUS's latest filing, from $158000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $487000.0 in Q1 2022 and troughed at -$357000.0 in Q2 2021.
- A 5-year average of $66200.0 and a median of $102500.0 in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2021 and 2023: Non Operating Income plunged 4362.5% in 2021, then soared 2500.0% in 2023.
- Over 5 years, Non Operating Income stood at $8000.0 in 2021, then tumbled by 187.5% to -$7000.0 in 2022, then jumped by 2500.0% to $168000.0 in 2023, then sank by 35.12% to $109000.0 in 2024, then tumbled by 49.54% to $55000.0 in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered $55000.0, $158000.0, and $106000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 111,000.00 |
| Dec 31, 2025 | 55,000.00 |
| Sep 30, 2025 | 158,000.00 |
| Jun 30, 2025 | 106,000.00 |
| Mar 31, 2025 | 119,000.00 |
| Dec 31, 2024 | 109,000.00 |
| Sep 30, 2024 | 160,000.00 |
| Jun 30, 2024 | 169,000.00 |
| Mar 31, 2024 | 193,000.00 |
| Dec 31, 2023 | 168,000.00 |
| Sep 30, 2023 | 281,000.00 |
| Jun 30, 2023 | 99,000.00 |
| Mar 31, 2023 | -21,000.00 |
| Dec 31, 2022 | -7,000.00 |
| Sep 30, 2022 | -47,000.00 |
| Jun 30, 2022 | -16,000.00 |
| Mar 31, 2022 | 487,000.00 |
| Dec 31, 2021 | 8,000.00 |
| Sep 30, 2021 | 6,000.00 |
| Jun 30, 2021 | -357,000.00 |